Renal Cell Carcinoma
VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.
Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
Researchers enrolled 6 and 49 patients into dose-finding and dose expansion stages, respectively.
Cancer Therapy Advisor asked Dr Gyawali, who coauthored a viewpoint just published in JAMA Oncology, to discuss the FDA's approval of sunitinib, and whether it is an example of what he calls "regulatory capture" in medicine.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
Previous studies found that an elevated pH environment leads to nearly a 40% reduction in pazopanib exposure.
Close to 60% of all patients with VHL will develop RCC or renal cysts.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
A shift toward multidisciplinary care is inevitable for the treatment of locally advanced and metastatic RCC.
Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.
Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.
Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.
Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
The phase 3 METEOR trial demonstrated that cabozantinib prolonged PFS, OS, and ORR compared with everolimus, but the impact on QoL was not fully established.
Access to treatment should be considered as important as the research leading to clinical improvements.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
The drug was, however, associated with a greater number of grade 3 to 4 adverse events.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.
The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.
A cumulative-use analysis suggests that NSAIDs, ACEis, and SSRIs improve disease-specific outcomes among patients with kidney cancer, and further that NSAIDs improve overall survival.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy